



Universiteit
Leiden
The Netherlands

Clinical, pathological and molecular prognostic factors in colorectal cancer

Vogelaar, F.J.

Citation

Vogelaar, F. J. (2017, March 23). *Clinical, pathological and molecular prognostic factors in colorectal cancer*. Retrieved from <https://hdl.handle.net/1887/46975>

Version: Not Applicable (or Unknown)

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/46975>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/46975> holds various files of this Leiden University dissertation

Author: Vogelaar, F.J.

Title: Clinical, pathological and molecular prognostic factors in colorectal cancer

Issue Date: 2017-03-23

7

Impact of anesthetic technique on survival in colon cancer: a review of the literature

F.J. Vogelaar, D.J. Lips, F.R.C. van Dorsten, V.E. Lemmens, K. Bosscha

Gastroenterol Rep. 2016 Feb;4(1):30-4.

ABSTRACT

An oncological surgical resection is the mainstay of treatment for potentially curable colon cancer. At the time of surgery, a large fraction of patients do harbour - although not visible - minimal residual disease at the time of surgery. The immunosuppression that accompanies surgery may have an effect on disease recurrence and survival. Regional or neuraxial anesthetic techniques like epidural anesthesia may suppress immune function less than opioid analgesia, by reducing stress response and significantly reducing exposure to opioids. Consistent with this hypothesis, regional anesthetic techniques have been associated with lower recurrence rates in breast cancer and prostate cancer. Results for colon cancer, however, are contradictory. In this review of the literature we describe all studies addressing the association of the use of epidural anesthesia and survival in colon cancer surgery.

INTRODUCTION

An oncological surgical resection is the mainstay of treatment for potentially curable colon cancer. However, even in stage I and II colonic cancer, 10-30% will develop recurrence of disease. It is known that, even with the best surgical technique, surgery for cancer is associated with release of tumor cells. Also it is noteworthy that, at the time of surgery, a large fraction of patients do harbour minimal residual disease, although this may not be visible. (1)

The idea that surgery itself can promote local cancer recurrence and metastasis is not novel and was already described in the 19th century by Velpeau, a French anatomist and surgeon, who noticed that surgical removal of cancer could be associated with the return of the disease and that the operation possibly tended to accelerate tumor growth. (2) Whether this results in recurrence of clinical cancer or metastasis depends largely on the balance between the tumor's ability to spread and the immunosurveillance of the patient. (3)

General anesthesia and surgical stress may suppress immunity by directly affecting the immune system or activating the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. (4) Pre-operative and post-operative opioids may inhibit cellular and humoral immune function in humans, and morphine itself might have a pro-angiogenic effect and promotes tumor growth. (5)

Regional or neuraxial anesthetic techniques may suppress immune function less than opioid analgesia by reducing stress response and significantly reducing exposure to opioids. Consistent with this hypothesis, regional anesthetic techniques have been associated with lower recurrence rates in breast cancer and prostate cancer. (6;7) Results for colon cancer, however, are contradictory. (8) In this review of the literature we describe all studies addressing the association of the use of epidural anesthesia (EA) and survival in colon cancer surgery.

METHODS

Relevant studies were sought in the Pubmed database (starting date January 1990 up to June 2014) using search terms as follows: (i) "regional anesthesia" or "regional anaesthesia" or "regional analgesia" or "anesthetic technique" or "anaesthetic technique", (ii) "recurrence" or "survival" and (iii) "colorectal cancer" or "colon cancer". Also, we searched "related citations" and reference lists to identify other articles. Only full papers published in the English language were included. We did not define a minimum of patients to qualify for inclusion in the analysis.

The following information was gathered from the articles: (i) number of included patients, (ii) design of the study, (iii) age, (iv) type of tumor (colon and/or rectal), (v) tumor stage, (vi) follow up, and (vii) effect of anesthetic technique on overall survival and cancer recurrence.

RESULTS

A total of seven studies were found addressing the impact of EA on survival in colorectal cancer surgery. (8-14) *Table 1* shows the characteristics of each of these.

Prospective studies

Two studies of these seven were prospective. Christopherson *et al.* studied long-term survival after resection of colon cancer as a sub-analysis of a prospective randomized study. This Veterans Affairs Co-operative Study No. 345 was initially designed to compare the short-term effect of general anesthesia with and without epidural anesthesia and analgesia supplementation in patients undergoing abdominal surgery. Randomization was stratified for type of surgery, age and cardiac risk. (9) The second prospective study was the Multicenter Australian Study of Epidural Anesthesia and Analgesia in Major Surgery (the MASTER trial), primarily designed to compare adverse outcomes in high-risk patients managed for major surgery with epidural block or alternative analgesic regimens with general anesthesia in a multicentre randomized trial. (14)

Overall survival

Christopherson *et al.* found a better overall survival in the first 1.5 postoperative years in 177 colon cancer patients for stage I-II patients with a mean age of 69 years old who received EA (HR 0.21 (95% CI 1.40-15.42) $p=0.012$). Nevertheless, the type of anesthesia did not appear to affect longterm survival. (9) Of 446 patients in the MASTER trial with a mean age of 70-71 years old undergoing major abdominal surgery for different types of cancer, 112 underwent surgery because of stage I-III colon cancer. They did not find that the use of EA ($n=58$) was associated with improved overall survival. (14)

Disease-free survival

Of the two prospective studies, only the MASTER trial assessed a disease-free survival analysis. EA in this study was not associated with improved disease-free survival.

Retrospective studies

Five retrospective studies were included in this review. Of all reviewed literature, the largest retrospective study was the Surveillance, Epidemiology, and End Results (SEER)-

Table 1. Characteristics of described studies

First author	Year of publication	Study design	No. of patients	Mean age (years)	Cancer type	Stage	Follow up (years)	OS benefit from EA	RFS benefit from EA
Christopherson	2008	Prospective	177 EA: 58 No EA: 92	69	Colon	I-IV	Up to 10 years	Better OS in stage I-III No benefit in stage III-IV	Not assessed
Gottschalk	2010	Retrospective	509 EA: 256 No EA: 253	64	Colon (n=283) Rectal (n=202) 'others' (n=25)	I-IV	Median, 1.8	Not assessed	Better RFS in older patients (≥ 65 years old)
Gupta	2011	Retrospective	655 EA: 562 No EA: 93	73 (colon) 69 (rectal)	Colon (n=360) Rectal (n=295)	I-III	Mean, 2.6	Better OS in rectal cancer	Not assessed
Myles	2011	Prospective	112* EA: 58 No EA: 54	71 (EA) 70 (no EA)	Colon	I-III	Up to 12 years	No benefit	No benefit
Day	2012	Retrospective	424 EA: 107 (251 including spinal) No EA: 173	72 (EA) 70 (PCA) 70 (spinal)	Colon (n=314) Rectal (n=110)	I-III (?) Not clearly described	Median, 3.1 (epidural) 2.3 (PCA) 1.4 (spinal)	No benefit	No benefit
Cummings	2012	Retrospective	42151 EA: 9670 No EA: 32481	≥ 66	Colon (n=33390) Rectal (n=8761)	I-III	Up to 14 years	Better OS	No benefit
Holler	2013	Retrospective	749 EA: 442 No EA: 307	Not available	Colon (n=369) Rectal (n=380)	I-IV	Up to 8 years	Better OS (especially in ASA classification 3 to 4)	Not assessed

*As a part of 446 patients undergoing major abdominal surgery for different types of cancer

EA=epidural anesthesia; OS= overall survival; PCA=patient-controlled analgesia; RFS=recurrence-free survival

based study with a large cohort of 42151 patients aged 66 years or older diagnosed with non-metastatic colorectal carcinoma. (8) Holler *et al* studied 749 stage I-IV colorectal cancer patients in their large retrospective analyses. (13) The Swedish study of Gupta *et al.*, with a total of 655 colorectal patients with a mean age of 69 (rectal cancer) and 73 (colon cancer) years old, excluded emergency operations, laparoscopic-assisted resections and stage IV in their analysis. (12) Day *et al.* studied colon- and rectal cancer patients with a mean age of 70 (no epidural) and 72 (epidural) years old. (10) All underwent a laparoscopic resection in this study. Patients received either an epidural (n=107), spinal block (n=144), or a morphine, patient-controlled analgesia (PCA) (n=173) for their primary postoperative analgesia. Gottschalk *et al* analysed stage I-IV patients (n=509) of which 283 with colon cancer, 202 with rectal cancer and 25 'others'. (11)

Overall survival

Four of the retrospective studies assessed overall survival analysis. The large SEER-based study found a significant association between EA and improved overall survival (HR 0.91 (95% CI 0.87-0.94) $p < 0.001$). (8) A significantly better overall survival was also found by Holler *et al.* in 442 patients who received EA (5 year survival rate with EA was 62%, but only 54% without EA; HR 0.73, $p < 0.02$). (13) The positive impact in this study was the most significant in high risk patients defined as American Association of Anaesthesiologists (ASA) classification 3 - 4 ($p = 0.006$). (13) The Swedish study found a reduction in all-cause mortality in rectal cancer patients (n=295) who received EA (HR 0.45 (95% CI 0.22-0.90) $p = 0.025$). (12) Day *et al.* found no overall survival difference in their analysis. (10)

Disease-free survival

In the study of Gottschalk *et al.* during median follow up of 1.8 years, EA was associated with a lower cancer recurrence in 248 patients older than 64 years ($p = 0.01$), but not in younger patients. (11) The SEER-based study adjusted for demographic and clinical covariates and did not find a significant difference in the odds of recurrence between the groups during a mean follow-up of 5 years. (8) Also no recurrence-free survival difference was found in the study of Day *et al.* (10)

DISCUSSION

Because the anti cancer immune response is a primary determinant of cancer progression, it is logical to hypothesize that interventions aimed at reducing exposure to immunosuppressive factors would improve patient outcomes after a potentially curative cancer resection. Although EA is theoretically supposed to be a favourable immune-

modulating intervention, not all studies show consistent beneficial effect from EA in colon cancer patients. Seven studies are included in this review, of which two had a prospective design. Four of the seven studies showed an overall survival benefit in patients receiving EA although, in three of these, the effect was only seen in subgroups (stage I-II in the first one and a half year postoperative, rectal cancer patients and ASA 3 - 4 patients). A cancer recurrence survival benefit of EA was found in one study in older patients. None of the studies found a negative effect of EA on recurrence-free or overall survival.

Because of the retrospective nature of five of the seven studies, unrecorded factors may have influenced survival: for example, potentially important treatment characteristics like the use of chemotherapy and radiation are missing in all studies except Gupta *et al* (12). Although, in some studies, tumor grade is known (11;13;14), other tumor-specific characteristics that influence prognosis - such as lymphangioinvasion, tumor perforation and microsatellite instability - are unknown.

It is hypothesised that volatile anesthesia and opioids may have a negative effect on the anti-cancer immune system, especially natural killer (NK) cells (5;15;16). EA might reduce the requirement of volatile anesthesia, and obviate the need for opioid administration. None of the studies give detailed information about the used analgetic and anesthetic techniques currently in use.

In two of the seven studies, only colon cancer patients were studied (9;14), while four studies analyzed colorectal cancer patients as one group (8;10;11;13). Only Gupta *et al* made a subanalysis for colon and rectal cancer. (12) As a possible explanation for the better survival for rectal cancer patients with EA in their study, they suggest that rectal cancer may be more susceptible to the protective effect of regional analgesia than colonic cancer patients. No specific pathophysiological mechanism for this hypothesis is given.

NK cells are the major responsible of cytotoxic activity against spontaneously derived tumor cells. Data from literature have shown that both the total and the relative number of circulating NK cells are greater in healthy elderly than in young adult ages. The age-related increase of NK-cell number can be regarded as a compensatory mechanism for the decreased cytolytic activity per cell in elderly subjects. Total NK-cell cytotoxicity is steady, but, the NK-cell cytotoxicity on a 'per cell' basis is impaired (17). Gottschalk *et al* suggested that the favorable benefit from EA on the immune system (and especially the NK cells) might be greater in older subjects, because they only found a recurrence-free survival benefit from EA in patients older than 64 years old (11). Although specific changes of the effect of EA on NK cells in elderly subjects might play a role in different results of the studies, the possible underlying mechanism needs to be further clarified in future studies.

Different surgical techniques may also have influenced the results, especially the laparoscopic versus open approaches. The study of Day *et al* only looked at patients receiving laparoscopic colorectal resections. (10) The reason why no survival advantage was identified with the use of regional analgesia in this study may be due to the laparoscopic approach. Laparoscopy is known to reduce the degree of immunosuppression that occurs during the postoperative period compared with that of an open colorectal resection. (18) If a significant preservation of immune function occurs with laparoscopic colorectal resection, the choice of analgesia used may be less important. On the other hand, a large number of trials comparing laparoscopic and open surgery for colorectal cancer can be identified in the literature. A recent meta-analysis stated that laparoscopic surgery for colon cancer does not differ from open surgery in terms of overall survival. (19) None of the prospective studies in our review stratified for the type of surgery (laparoscopic versus open).

Finally, the effect of EA might not only be anti-tumor, but also favour other mechanisms. Although cancer recurrence will determine survival to a large extent, other putative mechanisms include a reduction in perioperative cardiac-, respiratory- and thromboembolic events, but this effect mainly influences short-term survival. (20) A recent Cochrane review concluded that, compared with general anesthesia, a central neuraxial block may reduce the 0-30-day mortality for patients undergoing surgery with intermediate-to-high cardiac risk. (21)

CONCLUSIONS

This review of seven heterogeneous studies shows that the association between EA and survival for colon and rectal cancer is not clear, as conflicting results are described in literature - although none of the studies showed a negative influence of EA on survival. Randomized prospective, well stratified studies are needed to determine whether the association between EA and (cancer-specific) survival is causative.

REFERENCES

1. Denis MG, Lipart C, Leborgne J, LeHur PA, Galmiche JP, Denis M, Ruud E, Truchaud A, Lustenberger P. Detection of Disseminated Tumor Cells in Peripheral Blood of Colorectal Cancer Patients. *Int J Cancer* 1997; 74(5): 540-4.
2. Gottschalk A, Sharma S, Ford J, Durieux ME, Tiouririne M. Review Article: the Role of the Perioperative Period in Recurrence After Cancer Surgery. *Anesth Analg* 2010; 110(6): 1636-43.
3. Shakhar G, Ben-Eliyahu S. Potential Prophylactic Measures Against Postoperative Immunosuppression: Could They Reduce Recurrence Rates in Oncological Patients? *Ann Surg Oncol* 2003; 10(8): 972-92.
4. Kurosawa S, Kato M. Anesthetics, Immune Cells, and Immune Responses. *J Anesth* 2008; 22(3): 263-77.
5. Das J, Kumar S, Khanna S, Mehta Y. Are We Causing the Recurrence-Impact of Perioperative Period on Long-Term Cancer Prognosis: Review of Current Evidence and Practice. *J Anaesthesiol Clin Pharmacol* 2014; 30(2): 153-9.
6. Biki B, Mascha E, Moriarty DC, Fitzpatrick JM, Sessler DI, Buggy DJ. Anesthetic Technique for Radical Prostatectomy Surgery Affects Cancer Recurrence: a Retrospective Analysis. *Anesthesiology* 2008; 109(2): 180-7.
7. Exadaktylos AK, Buggy DJ, Moriarty DC, Mascha E, Sessler DI. Can Anesthetic Technique for Primary Breast Cancer Surgery Affect Recurrence or Metastasis? *Anesthesiology* 2006; 105(4): 660-4.
8. Cummings KC, III, Xu F, Cummings LC, Cooper GS. A Comparison of Epidural Analgesia and Traditional Pain Management Effects on Survival and Cancer Recurrence After Colectomy: a Population-Based Study. *Anesthesiology* 2012; 116(4): 797-806.
9. Christopherson R, James KE, Tableman M, Marshall P, Johnson FE. Long-Term Survival After Colon Cancer Surgery: a Variation Associated With Choice of Anesthesia. *Anesth Analg* 2008; 107(1): 325-32.
10. Day A, Smith R, Jourdan I, Fawcett W, Scott M, Rockall T. Retrospective Analysis of the Effect of Postoperative Analgesia on Survival in Patients After Laparoscopic Resection of Colorectal Cancer. *Br J Anaesth* 2012; 109(2): 185-90.
11. Gottschalk A, Ford JG, Regelin CC, You J, Mascha EJ, Sessler DI, Durieux ME, Nemergut EC. Association Between Epidural Analgesia and Cancer Recurrence After Colorectal Cancer Surgery. *Anesthesiology* 2010; 113(1): 27-34.
12. Gupta A, Bjornsson A, Fredriksson M, Hallbook O, Eintrei C. Reduction in Mortality After Epidural Anaesthesia and Analgesia in Patients Undergoing Rectal but Not Colonic Cancer Surgery: a Retrospective Analysis of Data From 655 Patients in Central Sweden. *Br J Anaesth* 2011; 107(2): 164-70.
13. Holler JP, Ahlbrandt J, Burkhardt E, Gruss M, Rohrig R, Knapheide J, Hecker A, Padberg W, Weigand MA. Peridural Analgesia May Affect Long-Term Survival in Patients With Colorectal Cancer After Surgery (PACO-RAS-Study): an Analysis of a Cancer Registry. *Ann Surg* 2013; 258(6): 989-93.
14. Myles PS, Peyton P, Silbert B, Hunt J, Rigg JR, Sessler DI. Perioperative Epidural Analgesia for Major Abdominal Surgery for Cancer and Recurrence-Free Survival: Randomised Trial. *BMJ* 2011; 342: d1491.
15. Maher DP, Wong W, White PF, McKenna R, Jr., Rosner H, Shamloo B, Louy C, Wender R, Yumul R, Zhang V. Association of Increased Postoperative Opioid Administration With Non-Small-Cell Lung Cancer Recurrence: a Retrospective Analysis. *Br J Anaesth* 2014; 113 Suppl 1: i88-i94.

16. Nguyen J, Luk K, Vang D, Soto W, Vincent L, Robiner S, Saavedra R, Li Y, Gupta P, Gupta K. Morphine Stimulates Cancer Progression and Mast Cell Activation and Impairs Survival in Transgenic Mice With Breast Cancer. *Br J Anaesth* 2014; 113 Suppl 1: i4-13.
17. Malaguarnera L, Cristaldi E, Malaguarnera M. The Role of Immunity in Elderly Cancer. *Crit Rev Oncol Hematol* 2010; 74(1): 40-60.
18. Evans C, Galustian C, Kumar D, Hagger R, Melville DM, Bodman-Smith M, Jourdan I, Gudgeon AM, Dalglish AG. Impact of Surgery on Immunologic Function: Comparison Between Minimally Invasive Techniques and Conventional Laparotomy for Surgical Resection of Colorectal Tumors. *Am J Surg* 2009; 197(2): 238-45.
19. Martel G, Crawford A, Barkun JS, Boushey RP, Ramsay CR, Fergusson DA. Expert Opinion on Laparoscopic Surgery for Colorectal Cancer Parallels Evidence From a Cumulative Meta-Analysis of Randomized Controlled Trials. *PLoS One* 2012; 7(4): e35292.
20. Rodgers A, Walker N, Schug S, McKee A, Kehlet H, van ZA, Sage D, Fitter M, Saville G, Clark T, MacMahon S. Reduction of Postoperative Mortality and Morbidity With Epidural or Spinal Anaesthesia: Results From Overview of Randomised Trials. *BMJ* 2000; 321(7275): 1493.
21. Guay J, Choi P, Suresh S, Albert N, Kopp S, Pace NL. Neuraxial Blockade for the Prevention of Postoperative Mortality and Major Morbidity: an Overview of Cochrane Systematic Reviews. *Cochrane Database Syst Rev* 2014; 1: CD010108.

